Lead Sponsor

GlaxoSmithKline

Age

2 - 2 years

Sex

ALL

Healthy Volunteers

Yes

•Male or female between, and including, 28-30 months of age at the time of first blood sampling.
•Subjects who previously participated in the 105553 and 107046 studies and who received a full four dose regimen of pneumococcal conjugate vaccine during the primary and booster studies.
•Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
•Written informed consent, covering visits 1, 2 and 3, obtained from the parent or guardian of the subject.
•Free of obvious health problems as established by medical history and clinical examination before entering into the study.

•Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the blood sampling
•Administration of any additional pneumococcal vaccine since end of 107046 study.
•Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the blood sampling.
•Administration of immunoglobulins and/or any blood products less than 6 months prior to blood sampling.
•Any confirmed or suspected immunosuppressive or immunodeficient condition since the end of the 107046 study, based on medical history and physical examination.

Related studies

NCT00907777 · Infections, Streptococcal, Streptococcus Pneumoniae

NCT00985751 · Infections, Streptococcal

NCT00489554 · Infections, Streptococcal, Streptococcus Pneumoniae Vaccines

NCT00814710 · Infections, Streptococcal, Streptococcus Pneumoniae

NCT00609492 · Infections, Streptococcal, Streptococcus Pneumoniae Vaccines

Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine